Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor, ErbB-2 | 8 | 2024 | 497 | 2.050 |
Why?
|
| Immunotherapy, Adoptive | 9 | 2025 | 790 | 1.740 |
Why?
|
| T-Lymphocytes | 14 | 2025 | 1679 | 1.660 |
Why?
|
| Glioblastoma | 8 | 2018 | 327 | 1.600 |
Why?
|
| Immunotherapy | 7 | 2021 | 662 | 1.070 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 4 | 2018 | 20 | 0.910 |
Why?
|
| Brain Neoplasms | 7 | 2020 | 1222 | 0.900 |
Why?
|
| Antigens, Neoplasm | 4 | 2020 | 394 | 0.900 |
Why?
|
| Receptors, Antigen, T-Cell | 8 | 2020 | 480 | 0.880 |
Why?
|
| Sarcoma | 2 | 2024 | 197 | 0.880 |
Why?
|
| Muscle Neoplasms | 1 | 2020 | 21 | 0.710 |
Why?
|
| Cancer Vaccines | 3 | 2020 | 187 | 0.660 |
Why?
|
| Tumor Escape | 2 | 2016 | 63 | 0.630 |
Why?
|
| Rhabdomyosarcoma | 1 | 2020 | 199 | 0.580 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2017 | 155 | 0.560 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1119 | 0.550 |
Why?
|
| Adoptive Transfer | 2 | 2014 | 237 | 0.500 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2014 | 193 | 0.390 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2023 | 1192 | 0.360 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1022 | 0.310 |
Why?
|
| Lymphocyte Depletion | 2 | 2024 | 122 | 0.280 |
Why?
|
| Transplantation Conditioning | 2 | 2018 | 322 | 0.260 |
Why?
|
| Mice, SCID | 3 | 2018 | 572 | 0.260 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2020 | 874 | 0.240 |
Why?
|
| Cyclophosphamide | 2 | 2024 | 422 | 0.240 |
Why?
|
| Immunological Synapses | 1 | 2025 | 26 | 0.240 |
Why?
|
| Membrane Microdomains | 1 | 2025 | 60 | 0.240 |
Why?
|
| Vidarabine | 1 | 2024 | 79 | 0.230 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 102 | 0.230 |
Why?
|
| Cell Line, Tumor | 4 | 2025 | 3301 | 0.210 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 47 | 0.210 |
Why?
|
| Antigens, CD19 | 2 | 2021 | 177 | 0.200 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 326 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 4 | 2020 | 1076 | 0.200 |
Why?
|
| Humans | 27 | 2025 | 122409 | 0.190 |
Why?
|
| Treatment Outcome | 6 | 2024 | 12036 | 0.190 |
Why?
|
| Lymphoma | 1 | 2024 | 323 | 0.180 |
Why?
|
| Leukemia | 1 | 2024 | 375 | 0.180 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 57 | 0.180 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 26 | 0.170 |
Why?
|
| Immunologic Memory | 1 | 2021 | 179 | 0.170 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 93 | 0.170 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 300 | 0.170 |
Why?
|
| Remission Induction | 1 | 2020 | 301 | 0.170 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 271 | 0.160 |
Why?
|
| Transgenes | 2 | 2020 | 336 | 0.160 |
Why?
|
| Osteosarcoma | 2 | 2019 | 259 | 0.160 |
Why?
|
| Ependymoma | 1 | 2020 | 134 | 0.160 |
Why?
|
| Bone Marrow | 1 | 2020 | 319 | 0.160 |
Why?
|
| Epigenomics | 1 | 2019 | 163 | 0.160 |
Why?
|
| Child | 12 | 2024 | 24108 | 0.160 |
Why?
|
| Receptor, EphA2 | 1 | 2018 | 26 | 0.150 |
Why?
|
| Antigenic Variation | 1 | 2018 | 39 | 0.150 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2017 | 22 | 0.150 |
Why?
|
| Alemtuzumab | 1 | 2018 | 88 | 0.150 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2018 | 65 | 0.150 |
Why?
|
| Neoplasms | 2 | 2022 | 2752 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 468 | 0.140 |
Why?
|
| Medulloblastoma | 1 | 2020 | 338 | 0.140 |
Why?
|
| Biopsy | 1 | 2020 | 1251 | 0.130 |
Why?
|
| Mice | 7 | 2021 | 17637 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2024 | 5970 | 0.130 |
Why?
|
| Protein Binding | 2 | 2020 | 1740 | 0.130 |
Why?
|
| Transplantation, Homologous | 1 | 2018 | 659 | 0.130 |
Why?
|
| Interleukin-13 | 1 | 2016 | 96 | 0.130 |
Why?
|
| Protein Multimerization | 1 | 2016 | 122 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 645 | 0.130 |
Why?
|
| HEK293 Cells | 2 | 2020 | 746 | 0.130 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 248 | 0.130 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 375 | 0.130 |
Why?
|
| Male | 11 | 2024 | 59575 | 0.130 |
Why?
|
| Microspheres | 1 | 2015 | 70 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2015 | 810 | 0.130 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 471 | 0.130 |
Why?
|
| Immediate-Early Proteins | 1 | 2015 | 58 | 0.120 |
Why?
|
| Viral Matrix Proteins | 1 | 2015 | 109 | 0.120 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 217 | 0.120 |
Why?
|
| Immunophenotyping | 1 | 2015 | 333 | 0.120 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 681 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 1008 | 0.110 |
Why?
|
| Adult | 7 | 2024 | 28743 | 0.110 |
Why?
|
| Animals | 8 | 2021 | 33891 | 0.110 |
Why?
|
| Phosphoproteins | 1 | 2015 | 401 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 675 | 0.110 |
Why?
|
| Child, Preschool | 7 | 2024 | 13837 | 0.100 |
Why?
|
| Aged | 4 | 2024 | 18777 | 0.100 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2025 | 263 | 0.100 |
Why?
|
| Female | 11 | 2024 | 64937 | 0.100 |
Why?
|
| Genomics | 1 | 2019 | 1475 | 0.100 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 803 | 0.090 |
Why?
|
| Middle Aged | 4 | 2024 | 25586 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 429 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 773 | 0.090 |
Why?
|
| Antigens, Viral | 1 | 2012 | 441 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 4984 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1234 | 0.080 |
Why?
|
| Cytomegalovirus | 3 | 2017 | 269 | 0.080 |
Why?
|
| Adolescent | 7 | 2024 | 18971 | 0.080 |
Why?
|
| Models, Biological | 1 | 2013 | 1439 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1622 | 0.070 |
Why?
|
| Infant | 5 | 2023 | 12347 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1677 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 655 | 0.060 |
Why?
|
| Pediatrics | 1 | 2014 | 1139 | 0.060 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2025 | 25 | 0.060 |
Why?
|
| CD28 Antigens | 1 | 2025 | 78 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2024 | 15878 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 44 | 0.050 |
Why?
|
| Survival Rate | 2 | 2017 | 2001 | 0.050 |
Why?
|
| Neutropenia | 1 | 2024 | 202 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 230 | 0.050 |
Why?
|
| Apoptosis | 2 | 2018 | 1792 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2018 | 2315 | 0.040 |
Why?
|
| Injections, Intraventricular | 1 | 2020 | 65 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 204 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 195 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 335 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2020 | 298 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 181 | 0.040 |
Why?
|
| Gene Editing | 1 | 2021 | 184 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 571 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 401 | 0.040 |
Why?
|
| Chimerism | 1 | 2018 | 28 | 0.040 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 28 | 0.040 |
Why?
|
| Pancytopenia | 1 | 2018 | 40 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2018 | 81 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 286 | 0.040 |
Why?
|
| Allografts | 1 | 2017 | 186 | 0.040 |
Why?
|
| Cerebellar Neoplasms | 1 | 2020 | 283 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2018 | 269 | 0.030 |
Why?
|
| Mutation | 2 | 2021 | 5786 | 0.030 |
Why?
|
| Young Adult | 2 | 2024 | 8805 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1082 | 0.030 |
Why?
|
| Proteomics | 1 | 2019 | 478 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 278 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2019 | 8113 | 0.030 |
Why?
|
| Polystyrenes | 1 | 2015 | 14 | 0.030 |
Why?
|
| Color | 1 | 2015 | 30 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 871 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 11 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1592 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 713 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 157 | 0.030 |
Why?
|
| Interleukin-13 Receptor alpha1 Subunit | 1 | 2014 | 6 | 0.030 |
Why?
|
| Immunotoxins | 1 | 2014 | 21 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 2442 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2017 | 638 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2017 | 663 | 0.030 |
Why?
|
| Cytokines | 1 | 2020 | 1288 | 0.030 |
Why?
|
| Leukocytes | 1 | 2015 | 204 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 113 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2015 | 261 | 0.030 |
Why?
|
| Antibodies | 1 | 2015 | 371 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 285 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 390 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2025 | 4514 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1005 | 0.030 |
Why?
|
| Cell Separation | 1 | 2012 | 237 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 474 | 0.020 |
Why?
|
| Recurrence | 1 | 2015 | 1412 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 2942 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2017 | 3231 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3008 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 1403 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 1431 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 815 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 2012 | 218 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 4310 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 4492 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2035 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 1889 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 4648 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3455 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 9868 | 0.010 |
Why?
|